Nanovibronix Inc is a medical technology company focusing on the development and commercialization of proprietary therapeutic ultrasound devices for a range of healthcare applications. Their innovative products utilize non-invasive ultrasonic technology designed to enhance pain management, promote healing, and improve overall patient care. The company aims to address unmet clinical needs by providing effective and user-friendly solutions that can be integrated into various treatment protocols, enhancing the quality of life for patients while building partnerships with healthcare professionals and institutions. Read More
NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of 291,204 shares of its common stock (or common stock equivalents), at an offering price of $7.01 per share of common stock (or per common stock equivalent) in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about September 17, 2025, subject to the satisfaction of customary closing conditions.
NanoVibronix shares are trading sharply higher on Monday. The company announced a new U.S. patent granted to its wholly-owned subsidiary, ENvue Medical Holdings.
Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,409,105 B2, titled “Insertion Device Positioning Guidance System and Method” on September 9, 2025 to ENvue Medical Holdings LLC (formerly ENvue Medical Holdings, Corp.), a wholly-owned subsidiary of the Company (“ENvue” or “ENvue Medical”).
NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,402,953 B2, titled “Insertion Device Positioning Guidance System and Method” on September 2, 2025 to ENvue Medical Holdings LLC (formerly ENvue Medical Holdings, Corp.), a wholly-owned subsidiary of the Company (“ENvue” or “ENvue Medical”). The patent protects the Company’s proprietary method of overlaying electromagnetic (EM) navigation data directly onto real-time medical imaging modalities such as X-ray, CT, ultrasound and MRI.
NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic devices, today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the “common stock”) at a ratio of 1 post-split share for every 10 pre-split shares. The reverse stock split will become effective at 4:05 p.m. ET on Monday, August 11, 2025. The Company’s common stock will continue to be traded on the Nasdaq Capital Market under the symbol NAOV and will begin trading on a split-adjusted basis when the market opens on Tuesday, August 12, 2025. The new CUSIP number for the common stock following the reverse stock split is 63008J884.
NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in therapeutic devices for enteral feeding, pain management and urological conditions, today announced it has entered into a definitive agreement with an institutional investor for the purchase and sale of 8,889 shares of Series H Convertible Preferred Stock (the “Preferred Stock”) with a total stated value of $8,888,889. The Preferred Stock is convertible into shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at an initial conversion price of $1.01, which such conversion price is equal to the closing price as reported on Nasdaq on the trading day immediately prior to signing of the definitive agreements and is subject to customary anti-dilution adjustments. The initial closing is expected to occur on or about July 21, 2025, subject to the satisfaction of customary closing conditions (the “Initial Closing”).
Peraso Inc. (NASDAQ: PRSO), a leading innovator in mmWave wireless solutions, has officially acknowledged receipt of an unsolicited, non-binding acquisition proposal from Mobix Labs, Inc. (NASDAQ: MOBX). The offer proposes a stock-for-stock exchange that values Peraso at approximately $1.20 per share, representing a 20% premium over its 30-day average closing price. However, Peraso is contesting several key points made in Mobix's June 26 press release.
Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.
